Research Mission

GRS and its mainstay clinical cannabis research entity Nightingale Bioscience are positioned to be a significant pioneer in the emerging cannabis pharmaceutical industry. GRS is establishing our territory as a drug maker in neuro pharma cannabinoid formulations and therapies. 

Current Study

Nightingale’s current research study aims to provide solid science-based evidence on the efficacy of Cannabis medicine in the ALS disease. Our initial drug formulation is aimed primarily at slowing the progression of the disease as well as Delay of Onset in high risk patients while improving Quality of Life symptoms relief.

Neurocannabinoid and Alternative Medicine

Our focuses aligned with our experts’ prior research and our acknowledgement of the neurological healing properties now known to exist in cannabis physiology. 

Neurocannabis Formulated FDA Drugs 

GRS is using our science exploits as a foundation to better the world’s understanding of clinical cannabis formulations. We are aiming to set the bar and establish precursor expectations for future FDA guidelines in cannabis medicine approval policies. As a result we also expect to introduce synergistic MND biomarkers and research methodologies through symbiotic cannabis clinical trial discoveries. 

Future Areas of Research
Cannabis in other Motor Neuron Diseases
Mycology (Psilocybin, Cordyceps)
Psychedelic and Consciousness Research